Fanconi Anemia (FA) is an autosomal recessive disease caused by deficiency of proteins in a cellular pathway which impacts chromosome stability, DNA cross-link response, embryonic development, cancer susceptibility and stem cell survival. At least eight different genes are known to exist and three of these have been isolated. However, the biochemical function(s) of the FANC proteins are currently not understood. In order to understand the pathway's function and develop improved therapy for this disease, we will clone additional FANC genes and develop knock- out mice of these already cloned. We have narrowed the location of the FA group D gene to <300 kb and together with Project 1 will complete its positional cloning. In addition, we will use microcell-mediated chromosome transfer to map additional FA genes and positionally clone them in the future. We have generated knock-out mice for FA group C and will use these animals to study the role of FANCC in DNA cross-link responses in vivo, the biology of hematopoietic stem cells in FA and as a model FANCC in DNA cross-link responses in vivo, the biology of hematopoietic stem cells in FA and as a model for preclinical gene therapy. We will also generate knock-out mice for FA groups A and D. These mutants and their cells will be studied jointly with Projects 1 and 3. Mice doubly mutant in different FANC genes and genes involved in mammalian cross-link repair will be generated to study their cancer proneness hematopoiesis and responses to DNA damaging agents.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Program Projects (P01)
Project #
5P01HL048546-08
Application #
6468007
Study Section
Project Start
2001-07-01
Project End
2002-06-30
Budget Start
Budget End
Support Year
8
Fiscal Year
2001
Total Cost
$124,146
Indirect Cost
Name
Oregon Health and Science University
Department
Type
DUNS #
009584210
City
Portland
State
OR
Country
United States
Zip Code
97239
Whiteaker, Jeffrey R; Zhao, Lei; Ivey, Richard G et al. (2018) Targeted mass spectrometry enables robust quantification of FANCD2 mono-ubiquitination in response to DNA damage. DNA Repair (Amst) 65:47-53
Kroeger Jr, Paul T; Drummond, Bridgette E; Miceli, Rachel et al. (2017) The zebrafish kidney mutant zeppelin reveals that brca2/fancd1 is essential for pronephros development. Dev Biol 428:148-163
Rondinelli, Beatrice; Gogola, Ewa; YĆ¼cel, Hatice et al. (2017) EZH2 promotes degradation of stalled replication forks by recruiting MUS81 through histone H3 trimethylation. Nat Cell Biol 19:1371-1378
Karras, Georgios I; Yi, Song; Sahni, Nidhi et al. (2017) HSP90 Shapes the Consequences of Human Genetic Variation. Cell 168:856-866.e12
Mouw, Kent W; Goldberg, Michael S; Konstantinopoulos, Panagiotis A et al. (2017) DNA Damage and Repair Biomarkers of Immunotherapy Response. Cancer Discov 7:675-693
Garbati, Michael R; Hays, Laura E; Rathbun, R Keaney et al. (2016) Cytokine overproduction and crosslinker hypersensitivity are unlinked in Fanconi anemia macrophages. J Leukoc Biol 99:455-65
Zhang, Qing-Shuo; Tang, Weiliang; Deater, Matthew et al. (2016) Metformin improves defective hematopoiesis and delays tumor formation in Fanconi anemia mice. Blood 128:2774-2784
Zhang, Haojian; Kozono, David E; O'Connor, Kevin W et al. (2016) TGF-? Inhibition Rescues Hematopoietic Stem Cell Defects and Bone Marrow Failure in Fanconi Anemia. Cell Stem Cell 18:668-81
Zhang, Qing-Shuo; Benedetti, Eric; Deater, Matthew et al. (2015) Oxymetholone therapy of fanconi anemia suppresses osteopontin transcription and induces hematopoietic stem cell cycling. Stem Cell Reports 4:90-102
Lombardi, Anne J; Hoskins, Elizabeth E; Foglesong, Grant D et al. (2015) Acquisition of Relative Interstrand Crosslinker Resistance and PARP Inhibitor Sensitivity in Fanconi Anemia Head and Neck Cancers. Clin Cancer Res 21:1962-72

Showing the most recent 10 out of 106 publications